Submitted: 30 June 2016; Revised: 1 July 2016; Accepted: 1 July 2016; Published online first: 4 July 2016 The European Medicines Agency's (EMA) decision to approve the use of CPT-13, an infliximab biosimilar, in the treatment of inflammatory bowel disease (IBD), has proven controversial. In two papers, Professor
No takes yet. Share an insight, caveat, or question.
GaBI Journal Editor (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: